

# Neil Fleshner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9688366/publications.pdf>

Version: 2024-02-01

102  
papers

2,556  
citations

257450

24  
h-index

206112

48  
g-index

104  
all docs

104  
docs citations

104  
times ranked

4022  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of metformin, statins and diet in men on active surveillance for prostate cancer. World Journal of Urology, 2022, 40, 61-69.	2.2	4
2	Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. Clinical Genitourinary Cancer, 2022, 20, e217-e226.	1.9	3
3	Have we mis-PRONOUNCED the cardiovascular risk of GnRH agonists? A critical appraisal of the PRONOUNCE trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 657-658.	3.9	2
4	Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers. Cancers, 2022, 14, 1004.	3.7	3
5	Factors Associated with Stent Change and Prognosis in Patients with Malignant Ureteral Obstruction. Journal of Endourology, 2022, 36, 1083-1090.	2.1	2
6	Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with synchronous or metachronous metastatic disease. Prostate, 2022, 82, 345-351.	2.3	4
7	Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT). Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
8	Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2022, , .	1.6	0
9	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. European Radiology, 2022, 32, 7544-7554.	4.5	8
10	The Suggested Unique Association Between the Various Statin Subgroups and Prostate Cancer. European Urology Focus, 2021, 7, 537-545.	3.1	12
11	The suggested chemopreventive association of metformin with prostate cancer in diabetic patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 191.e17-191.e24.	1.6	0
12	Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic disease. Canadian Urological Association Journal, 2021, 15, E545-E552.	0.6	3
13	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen receptor-targeted therapy for metastatic castration-resistant prostate cancer. Cancer, 2021, 127, 2587-2594.	4.1	16
14	A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?. European Urology Focus, 2021, 7, 506-507.	3.1	5
15	Biorepositories and Databanks for the Development of Novel Biomarkers for Genitourinary Cancer Prevention and Management. European Urology Focus, 2021, 7, 513-521.	3.1	0
16	The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat. Canadian Urological Association Journal, 2021, 15, E623-E629.	0.6	4
17	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2021, 4, e2114694.	5.9	11
18	Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. Cancers, 2021, 13, 3607.	3.7	9

#	ARTICLE	IF	CITATIONS
19	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155.	1.0	5
20	AUTHOR REPLY. <i>Urology</i> , 2021, 153, 155.	1.0	0
21	Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e1-431.e8.	1.6	2
22	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021, 300, 369-379.	7.3	34
23	First experiences with Lu-177 PSMA therapy in combination with Pembrolizumab or after pretreatment with Olaparib in single patients. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.249029.	5.0	15
24	Epidemiology and Prevention of Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 877-892.	5.4	190
25	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	3
26	Re: Jeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology Meetings. <i>Euro Urol</i> 2021;80:442-449. <i>European Urology</i> , 2021, 81, e51-e51.	1.9	1
27	The association of statin subgroups with lower urinary tract symptoms following a prostate biopsy. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	0
28	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 39.e1-39.e9.	1.6	9
29	Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up. <i>European Urology</i> , 2020, 77, 311-317.	1.9	99
30	Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma. <i>World Journal of Urology</i> , 2020, 38, 2547-2554.	2.2	10
31	The deleterious association between proton pump inhibitors and prostate cancer-specific mortality "a population-based cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 622-629.	3.9	6
32	Optimizing screening and management of cardiovascular health in prostate cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E458-E464.	0.6	9
33	Salvage Radiotherapy Following Partial Gland Ablation for Prostate Cancer: Functional and Oncological Outcomes. <i>European Urology Open Science</i> , 2020, 21, 1-4.	0.4	1
34	Psychological distress associated with active surveillance in patients younger than 70 with a small renal mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 603.e17-603.e25.	1.6	14
35	Utility of digital rectal examination in a population with prostate cancer treated with active surveillance. <i>Canadian Urological Association Journal</i> , 2020, 14, E453-E457.	0.6	11
36	A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 343-350.	1.9	33

#	ARTICLE	IF	CITATIONS
37	Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 1085-1093.	0.4	44
38	Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. Journal of Urology, 2020, 204, 416-426.	0.4	8
39	Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease. Journal of Urology, 2020, 204, 466-475.	0.4	24
40	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. Journal of Urology, 2020, 204, 476-482.	0.4	7
41	Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?. Journal of Urology, 2020, 204, 1187-1194.	0.4	9
42	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (<sup>18</sup>F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. Journal of Clinical Oncology, 2020, 38, 5553-5553.	1.6	1
43	Novel androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer: A network meta-analysis.. Journal of Clinical Oncology, 2020, 38, 131-131.	1.6	2
44	Reply by Authors. Journal of Urology, 2020, 203, 1093-1093.	0.4	0
45	A narrative review of pelvic lymph node dissection in prostate cancer. Translational Andrology and Urology, 2020, 9, 3049-3055.	1.4	9
46	Reply by Authors. Journal of Urology, 2020, 204, 1194-1194.	0.4	0
47	Reply by Authors. Journal of Urology, 2020, 204, 475-475.	0.4	0
48	Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial. European Urology, 2019, 75, 300-309.	1.9	99
49	Lynch Syndrome in Urologic Malignancies – What Does the Urologist Need to Know?. Urology, 2019, 134, 24-31.	1.0	10
50	Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis. Canadian Urological Association Journal, 2019, 14, 36-41.	0.6	5
51	Age Differences in Patient-reported Psychological and Physical Distress Symptoms in Bladder Cancer Patients – A Cross Sectional Study. Urology, 2019, 134, 154-162.	1.0	5
52	Extraprostatic Extension in Core Biopsies Epitomizes High-risk but Locally Treatable Prostate Cancer. European Urology Oncology, 2019, 2, 88-96.	5.4	7
53	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. Canadian Urological Association Journal, 2019, 13, E292-E299.	0.6	0
54	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3

#	ARTICLE	IF	CITATIONS
55	GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture. <i>European Urology Oncology</i> , 2019, 2, 231-238.	5.4	9
56	Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. <i>Histopathology</i> , 2019, 74, 474-482.	2.9	44
57	Analysis of a practical surgical skills laboratory for nerve sparing radical prostatectomy. <i>World Journal of Urology</i> , 2019, 37, 799-804.	2.2	3
58	Germ Cell Testicular Tumors—Contemporary Diagnosis, Staging and Management of Localized and Advanced disease. <i>Urology</i> , 2019, 125, 8-19.	1.0	19
59	Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study. <i>Journal of Urology</i> , 2019, 202, 1159-1165.	0.4	8
60	Editorial Comment. <i>Journal of Urology</i> , 2019, 202, 504-505.	0.4	1
61	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 1165-1165.	0.4	0
62	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20.	1.6	7
63	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , 2018, 199, 1182-1187.	0.4	22
64	A urine-based DNA methylation assay, ProCuRE, to identify clinically significant prostate cancer. <i>Clinical Epigenetics</i> , 2018, 10, 147.	4.1	26
65	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.4	2
66	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. <i>Canadian Urological Association Journal</i> , 2018, 12, E281-97.	0.6	9
67	Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide. <i>European Urology Oncology</i> , 2018, 1, 238-241.	5.4	25
68	Quality indicators in the management of bladder cancer: A modified Delphi study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 328-334.	1.6	29
69	A Prostate Cancer “Nimbus” Genomic Instability and SCHLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. <i>European Urology</i> , 2017, 72, 665-674.	1.9	142
70	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , 2017, 120, 76-82.	2.5	23
71	Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors. <i>Oncology Letters</i> , 2017, 14, 390-396.	1.8	19
72	Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. <i>Oncotarget</i> , 2017, 8, 25928-25941.	1.8	16

#	ARTICLE	IF	CITATIONS
73	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , 2016, 10, 424.	0.6	6
74	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , 2016, 196, 1645-1650.	0.4	19
75	Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 395-406.	2.8	46
76	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , 2016, 195, 307-312.	0.4	9
77	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. <i>Canadian Urological Association Journal</i> , 2016, 10, 46.	0.6	55
78	Salvage HIFU for biopsy confirmed local prostate cancer recurrence after radical prostatectomy and radiation therapy: Case report and literature review. <i>Canadian Urological Association Journal</i> , 2015, 9, 671.	0.6	1
79	Time from first detectable PSA following radical prostatectomy to biochemical recurrence: A competing risk analysis. <i>Canadian Urological Association Journal</i> , 2015, 9, 14.	0.6	5
80	Spatial genomic heterogeneity within localized, multifocal prostate cancer. <i>Nature Genetics</i> , 2015, 47, 736-745.	21.4	395
81	Novel Multiplex MethyLight Protocol for Detection of DNA Methylation in Patient Tissues and Bodily Fluids. <i>Scientific Reports</i> , 2015, 4, 4432.	3.3	38
82	Active surveillance in patients with a PSA >10 ng/mL. <i>Canadian Urological Association Journal</i> , 2014, 8, 702.	0.6	12
83	Is pathology necessary to predict mortality among men with prostate-cancer?. <i>BMC Medical Informatics and Decision Making</i> , 2014, 14, 114.	3.0	2
84	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. <i>Canadian Urological Association Journal</i> , 2014, 8, 24.	0.6	44
85	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. <i>Journal of Urology</i> , 2014, 192, 1088-1093.	0.4	6
86	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. <i>European Urology</i> , 2014, 66, 619-622.	1.9	57
87	Metformin Use and All-Cause and Prostate Cancer-Specific Mortality Among Men With Diabetes. <i>Journal of Clinical Oncology</i> , 2013, 31, 3069-3075.	1.6	240
88	Is there ageism in prostate cancer detection?. <i>Canadian Urological Association Journal</i> , 2013, 3, 211.	0.6	1
89	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012, 7, 1037-1045.	2.7	42
90	High-dose oral vitamin D3 administration increases serum and prostate levels of vitamin D metabolites safely in prostate cancer patients. <i>FASEB Journal</i> , 2012, 26, 388.5.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Multidimensional protein identification technology analysis highlights mitoxantrone-induced expression modulations in the primary prostate cancer cell proteome. <i>Proteomics - Clinical Applications</i> , 2009, 3, 347-358.	1.6	1
92	Delay in the progression of low-risk prostate cancer: Rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. <i>Contemporary Clinical Trials</i> , 2007, 28, 763-769.	1.8	67
93	Major role for 5-alpha reductase inhibitors in the aging male. <i>Canadian Urological Association Journal</i> , 2007, 1, 22.	0.6	0
94	Prostate cancer prevention. <i>Cancer</i> , 2007, 110, 1889-1899.	4.1	60
95	Surgical wait times for patients with urological cancers: a survey of Canadian surgeons. <i>Canadian Journal of Urology</i> , 2006, 13 Suppl 3, 3-13.	0.0	8
96	EVIDENCE FOR CONTAMINATION OF HERBAL ERECTILE DYSFUNCTION PRODUCTS WITH PHOSPHODIESTERASE TYPE 5 INHIBITORS. <i>Journal of Urology</i> , 2005, 174, 636-641.	0.4	64
97	Defining high-risk prostate cancer: current status. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 1, 14-7; discussion 94-6.	0.0	5
98	Prostate cancer: chemoprevention update 2005. <i>Canadian Journal of Urology</i> , 2005, 12 Suppl 2, 2-4.	0.0	2
99	Dietary Fat and Prostate Cancer. <i>Journal of Urology</i> , 2004, 171, S19-24.	0.4	83
100	Role of saturation biopsy in the detection of prostate cancer among difficult diagnostic cases. <i>Urology</i> , 2002, 60, 93-97.	1.0	115
101	Controversies in the management of testicular seminoma. <i>Urologic Oncology</i> , 2002, 20, 227-233.	1.5	8
102	Outcomes of 200 Patients with Localized Prostate Cancer Enrolled in a Watchful Waiting Protocol. <i>UroOncology</i> , 2002, 2, 93-94.	0.1	0